A previous study had measured the safety and tolerability of tenofovir in both sexually active and abstinent women.
The entrance criteria were such that, based on risk factors in the participants' lifestyles, the study expected 92 infections to occur approximately 16 months after they recruited the final volunteer.
[5] Michel Sidibé of UNAIDS described the results of the study as being very encouraging because the treatment "can be controlled by women, and put in 12 hours earlier, and that is empowering.
"[6] Anthony Fauci of NIAID stated that "This is the first study that has shown a clear-cut positive effect of a microbicide on blocking acquisition of HIV infection.
"[7] Mitchell Warren, head of the AIDS Vaccine Advocacy Coalition, remarked that "This is a really historic day for HIV prevention research.